There is substantial evidence that moderate consumption of alcohol is associated with a lower risk of mortality, cardiovascular disease, stroke, type 2 diabetes, and cognitive decline and dementia in old age. It is still not proven whether wine consumption is associated with lower risks than consumption of other forms of alcohol such as beer or distilled spirits, but systematic reviews suggest that this may be the case at least for cognitive decline and dementia. However, a causal relationship has been questioned by some, with suggestions that health status and social factors may confer the benefits, especially for wine drinkers who are more often female, better educated, health conscious, non-smokers and temperate drinkers. Nevertheless, plausible biological mechanisms explain the benefits of alcohol and wine, and the relative specificity of the inverse relationship of moderate drinking to various human ailments is a strong point for causality.

Wine has unique properties quite separately from its alcohol content. Unlike beer and spirits, wine contains a variety of polyphenolic compounds which are extracted from the grapes during vinification. Mainly in the form of flavonoids like quercetin and stilbenes such as resveratrol, these polyphenols are contained in grape tannins and anthocyanin pigments and achieve higher levels in red than in white or rosé wines. Nevertheless, they are present in only small quantities, corresponding to about 250 mg/L in white and 1500 mg/L in red wines.

Resveratrol is just a minor component but has received the greatest research and lay attention, and ways have been described to enhance vastly its content in wine. Resveratrol, like all wine polyphenols, has antioxidant properties but also seems to modulate nitric oxide synthesis and promote vasodilatation. Importantly, it attenuates amyloid neuropathology in cell and animal models of Alzheimer’s disease, and restores cognitive function. Its ability to enhance the effects of a family of longevity genes called sirtuins has led to the synthesis of analogs of resveratrol, one of which, SRT501, has recently completed clinical trials in diabetes and obesity.

Resveratrol is a mixture of cis- and trans-isomers. Most of the research has been carried out with the naturally occurring trans-isomer, which is found in peanuts and Japanese knotweed as well as wine grapes and various types of berries. Until recently, the oral bioavailability problem of both flavonoids and stilbenes has been a stumbling block to proper research in humans – they are well absorbed when taken orally but are rapidly metabolized and eliminated. Glucoside derivatives of quercetin did demonstrate better bioavailability than quercetin itself when given orally, and resulted in inhibition

Correspondence: Roger M Pinder
2 St Wilfrid’s Court, Monkgate,
York YO31 7UQ, UK
Tel +44 1904 646684
Email roger.pinder@gmail.com
of platelet aggregation.\(^{18}\) However, plasma concentrations of resveratrol and its metabolites are low and transient after oral administration of the compound itself or in the form of red wine.\(^{16,17}\) Furthermore, faced with the very low bioavailability of resveratrol and the poor chances of a polar and scarcely lipophilic molecule passing the blood–brain barrier to achieve pharmacologically active levels in the human brain, any prospects of measuring a central effect were long regarded as minimal. Nevertheless, the application of modern brain imaging technology has recently defied the odds and demonstrated a central action of oral resveratrol.\(^{19}\)

David Kennedy and colleagues at Northumbria University in the UK assessed localized cerebral blood flow variables and cognitive performance in 22 healthy human adults in a randomized, double-blind, placebo-controlled, crossover study using near-infrared spectroscopy.\(^{19}\) The presence of resveratrol and its conjugates/metabolites in plasma were confirmed after the same doses of 250 or 500 mg of trans-resveratrol in a separate cohort. Resveratrol administration produced dose-dependent increases in cerebral blood flow during performance of a selection of cognitive tasks that activate the frontal cortex. Enhanced oxygen extraction was also apparent during task performance after both doses of resveratrol, although cognitive function was unaffected.

It seems that, in addition to the association of moderate wine consumption with a lowered risk for cognitive decline and dementia,\(^{10}\) one of the many polyphenols contained in wine may actually enter the brain after oral administration and activate cerebral blood flow upon cognitive demand.\(^{19}\) Given the very real effects of resveratrol on Alzheimer’s disease neuropathology and the associated cognitive deficits in animal models, it may well be worth considering a clinical trial of resveratrol in cognitively impaired older humans or in predementia syndromes like mild cognitive impairment. The latest data should encourage the search for synthetic analogs of wine polyphenols, particularly resveratrol, which will have greater oral bioavailability and enhanced brain penetration for the treatment of cognitive decline and dementia.

References